IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
IceCure Medical (NASDAQ: ICCM) has received a Notice of Allowance from the U.S. Patent and Trademark Office for its next-generation XSense™ cryoprobe technology. The innovation enhances the company's liquid-nitrogen-based cryoablation platform, which is used for tumor destruction through freezing as an alternative to surgical removal.
The patented technology features a novel extraction method incorporating a heater, temperature sensor, and controlled gas pulses in the cryoprobe's tip. This advancement enables precise temperature management during probe extraction, reducing tissue trauma risk. The XSense™ System with Cryoprobes has already secured regulatory approval in both the U.S. and Israel.
IceCure Medical (NASDAQ: ICCM) ha ricevuto una Notifica di Concessione dall'U.S. Patent and Trademark Office per la sua tecnologia di prossima generazione XSense™ cryoprobe. L'innovazione potenzia la piattaforma di crioablazione basata su azoto liquido, impiegata per la distruzione dei tumori mediante congelamento come alternativa all'asportazione chirurgica.
La tecnologia brevettata presenta un nuovo metodo di estrazione che integra un riscaldatore, un sensore di temperatura e impulsi di gas controllati nella punta del cryoprobe. Questo avanzamento permette una gestione precisa della temperatura durante l'estrazione della sonda, riducendo il rischio di traumi ai tessuti. Il sistema XSense™ con cryoprobes ha già ottenuto l'approvazione regolatoria sia negli Stati Uniti che in Israele.
IceCure Medical (NASDAQ: ICCM) ha recibido una Notificación de Concesión por parte de la Oficina de Patentes y Marcas de Estados Unidos para su tecnología de próxima generación XSense™ cryoprobe. La innovación mejora la plataforma de criocirugía basada en nitrógeno líquido, utilizada para la destrucción de tumores mediante congelación como alternativa a la extirpación quirúrgica.
La tecnología patentada presenta un nuevo método de extracción que incorpora un calentador, un sensor de temperatura y pulsos de gas controlados en la punta del crioprobo. Este avance permite una gestión precisa de la temperatura durante la extracción de la sonda, reduciendo el riesgo de daño a los tejidos. El sistema XSense™ con crioprobes ya ha recibido aprobación regulatoria en EE. UU. e Israel.
IceCure Medical (NASDAQ: ICCM)은 미국 특허상표청으로부터 차세대 XSense™ 크라이오프로브 기술에 대한 허가 통지를 받았습니다. 이 혁신은 고정된 질소 기반의 냉동 소작 플랫폼을 향상시켜, 종양을 절제 수술 대신 냉동 파괴하는 데 사용됩니다.
특허 기술은 크라이오프로브 끝에 히터, 온도 센서, 제어된 가스 펄스를 포함하는 새로운 추출 방법을 특징으로 합니다. 이 발전은 프로브 추출 중 온도 관리를 정확하게 해 조직 손상 위험을 줄입니다. XSense™ 시스템과 크라이오프로브는 이미 미국과 이스라엘에서 규제 승인을 받았습니다.
IceCure Medical (NASDAQ: ICCM) a reçu une Notice d'Autorisation de l'Office américain des brevets et des marques (USPTO) pour sa technologie de cryoprobe de prochaine génération XSense™. L'innovation améliore la plateforme de cryoablation à base d'azote liquide, utilisée pour détruire les tumeurs par congelation comme alternative à l'ablation chirurgicale.
La technologie brevetée présente une nouvelle méthode d'extraction intégrant un chauffe-eau, un capteur de température et des impulsions de gaz contrôlées à l'extrémité du cryoprobe. Cette avancée permet une gestion précise de la température lors de l'extraction de la sonde, réduisant le risque de traumatisme tissulaire. Le système XSense™ avec cryoprobes a déjà obtenu une approbation réglementaire aux États-Unis et en Israël.
IceCure Medical (NASDAQ: ICCM) hat vom United States Patent and Trademark Office eine Zulassungsbenachrichtigung für seine künftige XSense™ Cryoprobe-Technologie erhalten. Die Innovation verbessert die mit flüssigem Stickstoff arbeitende Kryoablation-Plattform des Unternehmens, die zur Zerstörung von Tumoren durch Einfrieren als Alternative zur chirurgischen Entfernung eingesetzt wird.
Die patentierte Technologie verfügt über eine neuartige Extraktionsmethode, die Heizer, Temperatursensor und kontrollierte Gasimpulse an der Spitze des Cryoprobe integriert. Dieser Fortschritt ermöglicht eine präzise Temperatursteuerung während der Sondenextraktion und senkt das Risiko von Gewebetrauma. Das XSense™-System mit Kryoproben hat bereits zulassungsrechtliche Genehmigungen in den USA und in Israel erhalten.
IceCure Medical (NASDAQ: ICCM) تلقّت إشعاراً بالسماح من مكتب براءات الاختراع والعلامات التجارية الأمريكي لنظام XSense™ cryoprobe من الجيل القادم. هذه الابتكار يعزز منصة التجميد باستخدام النيتروجين السائل للكشف عن الأجسام الورمية عبر التجميد كبديل لاستئصال جراحي.
التقنية المحمية ببراءة تتضمن طريقة استخراج جديدة تشتمل على مُسْتَلِزَم تسخين، ومُستشعر درجة الحرارة، ونبضات غاز محكومة في طرف Cryoprobe. هذا التقدم يتيح إدارة دقيقة لدرجة الحرارة أثناء استخراج المجس، مما يقلل من مخاطر إصابة الأنسجة. نظام XSense™ مع كريوبروبات قد حصل بالفعل على الموافقة التنظيمية في الولايات المتحدة وإسرائيل.
IceCure Medical (NASDAQ: ICCM) 已从美国专利商标局获得一份允许通知，适用于其下一代XSense™ 冰探头技术。该创新增强了以液氮为基础的低温消融平台，用于通过冷冻来破坏肿瘤，作为外科切除的替代方案。
这项专利技术具备一种新颖的提取方法，在探头尖端集成了加热器、温度传感器和受控气体脉冲。这一进步实现了探头提取过程中的温度精确控制，降低组织损伤风险。搭载 Cryoprobes 的 XSense™ 系统已在美国和以色列获得监管批准。
- None.
- None.
Insights
IceCure's new patent strengthens its position in cryoablation market with improved extraction technology reducing tissue trauma risks.
This patent allowance represents a significant advancement in IceCure's cryoablation technology portfolio. The innovation specifically addresses the critical extraction phase of cryoablation procedures—often overlooked but essential for patient outcomes. The newly patented technology incorporates an ingenious combination of a heater, temperature sensor, and controlled gas pulses that work in concert to manage the external surface temperature of the cryoprobe while embedded in frozen tissue.
What makes this development particularly valuable is its dual benefit of enhancing both clinical outcomes and operational efficiency. By precisely controlling the cryoprobe's temperature during extraction, the technology minimizes the risk of tissue trauma, which directly translates to improved patient recovery and potentially reduced procedural complications. The integration with their XSense™ system, which recently cleared regulatory hurdles in both the U.S. and Israeli markets, creates a comprehensive technological ecosystem.
From an intellectual property perspective, this patent strengthens IceCure's competitive position in the growing minimally-invasive tumor treatment market. The technology's versatility across multiple cryoprobe types indicates a well-designed platform approach rather than a single-application solution, maximizing its commercial potential across various clinical applications. This patent complements their flagship ProSense® system and builds upon their liquid-nitrogen-based technology foundation, creating multiple layers of IP protection.
The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience
XSense™ System with Cryoprobes recently received regulatory approval in the
"Our industry-leading liquid-nitrogen-based cryoablation platform has been further advanced with this latest invention, a cryoprobe technology," stated IceCure's Chief Executive Officer, Eyal Shamir. "There is an abundance of data, much of it from independent studies, showing that minimally invasive cryoablation procedures with our flagship ProSense® system have resulted in an improved patient experience with excellent medical outcomes. This new cryoprobe technology, which is integrated in our next-generation XSense™ system, further reduces any potential risk of tissue trauma as the cryoprobe is extracted from the patient at the end of the short, minimally invasive outpatient procedure."
This invention introduces a novel method for safely and efficiently extracting the cryoprobe after tissue freezing during cryoablation procedures. The cryoprobe's tip is integrated with a heater, temperature sensor, and controlled gas pulses, enabling precise estimation and management of the cryoprobe's external surface temperature—even while embedded in frozen tissue. Designed to be compatible with a wide range of XSense™ system cryoprobe types, the new cryoprobe technology is a versatile solution for multiple clinical scenarios.
About IceCure's Cryoablation Systems
IceCure's platform technology, including the ProSense® Cryoablation System and XSense™ Cryoablation System and CryoProbes, provides a minimally invasive treatment option to destroy tumors by freezing them. The systems uniquely harness the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
IceCure's cryoablation systems enhance patient and provider value by accelerating recovery, reducing pain, surgical risks and complications. With easy, transportable design and liquid nitrogen utilization, ProSense® and XSense™ open the door to fast and convenient office-based procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: that data show that minimally invasive cryoablation procedures with the ProSense® system have resulted in an improved patient experience with excellent medical outcomes and that the ProSense® system reduces any potential risk of tissue trauma and the versatile prospective design compatibility with a wide range of XSense™ system cryoprobe types. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-granted-notice-of-allowance-for-us-patent-for-its-next-generation-xsense-cryoprobes-302560245.html
SOURCE IceCure Medical
FAQ
What is the new patent granted to IceCure Medical (NASDAQ: ICCM)?
What are the key benefits of IceCure's new XSense™ cryoprobe technology?
Where has IceCure's XSense™ System received regulatory approval?
How does IceCure's cryoablation technology work?
What makes IceCure's new cryoprobe technology versatile?
